MUVON Completes Patient Enrollment of Randomized Phase 2 Clinical Study Evaluating Muscle Precursor Cell (MPC)-based Therapy in Stress Urinary Incontinence and Expects Topline Data in Q3 2025

Zurich, Switzerland, April 16, 2025 – MUVON Therapeutics AG, an innovative clinical-stage biotechnology company, announces dosing of the last patient in its phase 2 clinical study.

MUVON Therapeutics, an award-winning, clinical-stage biotechnology company focused on developing a novel platform for the regeneration of skeletal muscle tissue targeting Stress Urinary Incontinence, which affects over 200 million women globally, today announced that its ongoing phase 2 clinical study is now fully enrolled.

The recent interim readout of the SUISSE MPC2 study (NCT05534269) assessing the safety and efficacy of MUVON’s Muscle Precursor Cell (MPC)-based therapy in Stress Urinary Incontinence included evaluable data from 10 female patients with at least 6-months follow-up post injection of the tissue engineered product into the urethral sphincter muscle. MUVON Therapeutics has now dosed a total of 30 patients and met the study’s enrollment target. The company remains on track for the release of the final data from the completed phase 2 study in Q3 2025.

“We’re delighted to have reached this important milestone in our lead program which is designed to study the clinical outcomes post injection of MUVON’s tissue engineered product into the urethral sphincter muscle in female patients suffering from highly debilitating stress urinary incontinence” said Deana Mohr, Chief Executive Officer at MUVON Therapeutics. “With important data readouts expected in 2025, we’re getting closer to answering the key question if MUVON’s autologous cell-based therapy can transform the current treatment paradigm in addressing the high unmet medical need of stress urinary incontinence and wish to thank the patients and their families for their commitment to studying this innovative, first-in-class treatment option in the clinic.”

For more information, please contact:

Dr Deana Mohr, CEO

info@muvon-therapeutics.ch

About MUVON Therapeutics AG

Founded in 2020, MUVON Therapeutics is a clinical-stage life science spin-off from the University of Zurich currently being accelerated by the Wyss Zurich Translational Center. MUVON Therapeutics is dedicated to the discovery and development of personalized regenerative treatments with the goal of establishing them as an affordable standard of care, with an initial focus on the treatment of stress urinary incontinence in women. Our mission is to help the millions of patients suffering from serious debilitating diseases regain control of their lives by offering them minimally invasive treatment for regeneration of skeletal muscle tissue. For more information about MUVON Therapeutics, please visit: www.muvon-therapeutics.com